Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.

@article{Escudier2009PhaseIS,
  title={Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.},
  author={Bernard Escudier and Jan Roigas and Silke Gillessen and Ulrika Harmenberg and Sandhya Srinivas and Sasja F. Mulder and George Fountzilas and Christian Peschel and Per Flodgren and Edna Chow Maneval and Isan Chen and Nicholas John Vogelzang},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 25},
  pages={4068-75}
}
PURPOSE Sunitinib has demonstrated antitumor activity in metastatic renal cell carcinoma (mRCC) when given at 50 mg/d on a 4-weeks-on 2-weeks-off regimen. Herein, we report results of an open-label, multicenter phase II mRCC study of sunitinib administered on a continuous once-daily dosing regimen. PATIENTS AND METHODS Eligibility criteria included histologically proven mRCC with measurable disease, failure of one prior cytokine regimen, and good performance status. Patients were randomly… CONTINUE READING
Highly Influential
This paper has highly influenced 11 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
91 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 91 extracted citations

Similar Papers

Loading similar papers…